Home
OE Originals
OE Insights
CME
All Specialties
Arthroplasty
Cannabis
Ev. Based Medicine
Foot & Ankle
General Orthopaedics
Hand & Wrist
Metabolic Disorders
Osteoarthritis
Pediatric Orthopaedics
Peri-Operative
Phys. Therapy & Rehab
Shoulder & Elbow
Spine
Sports Medicine
Trauma
Tumour

Author Interviews

Conference Reports

PeerView

All Videos
(153 Videos)

Education
(12 Videos)
Innovation
(4 Videos)
Leadership
(6 Videos)
OrthoJoe
(28 Videos)
Other
(45 Videos)
Personal Growth
(3 Videos)
Practice
(19 Videos)
Research
(34 Videos)

COVID-19 Resource Center

OE World Tour

OE Perspectives

OE Ideas

OE Recommends

To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover
Metabolic Disorders

Male glucocorticoid-induced osteoporosis: teriparatide more effective than risedronate

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
September 2013
Metabolic Disorders High Impact Icon

Male glucocorticoid-induced osteoporosis: teriparatide more effective than risedronate

Vol: 2| Issue: 8| Number:14| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial

J Bone Miner Res. 2013 Jun;28(6):1355-68. doi: 10.1002/jbmr.1870

Contributing Authors:
CC Gluer F Marin JD Ringe F Hawkins R Moricke N Papaioannu P Farahmand S Minisola G Martinez JM Nolla C Niedhart N Guanabens R Nuti E Martin-Mola F Thomasius G Kapetanos J Pena C Graeff H Petto B Sanz A Reisinger PK Zysset

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

92 men with glucocorticoid-induced osteoporosis (GIO) were randomized to receive either daily injections of 20 ug teriparatide or weekly oral tablets of 35 mg risedronate to determine the effects of these treatments on improvements in bone mineral density (BMD), as assessed with dual X‐ray absorptiometry (DXA) and high-resolution quantitative computed tomography (HRQCT). Results indicated that, al...

To view the full content, login to your account,
or start your 30-day FREE Trial today.

FREE TRIAL Forgot Password?

Explore some of our unlocked ACE Reports below!

 Zoledronic acid increases BMD and prevents fracture risks in women with osteoporosis
Effects of 2.5mg zoledronate are long-lasting and similar to 5mg dose in osteopenic women
Network meta-analysis of current drug options for the treatment of osteoporosis in men
Immediate effects on bone metabolism biomarkers noted with resistance training and walking
Ace Report Preview Image
CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

The OE High Impact metric uses AI to determine the impact a study will have by considering the content of the article itself. Built using the latest advances of natural language processing techniques. OE High Impact predicts an article’s future number of citations than impact factor alone.

Continue